CN105142669B - 基于crispr的基因组修饰和调控 - Google Patents

基于crispr的基因组修饰和调控 Download PDF

Info

Publication number
CN105142669B
CN105142669B CN201380072477.4A CN201380072477A CN105142669B CN 105142669 B CN105142669 B CN 105142669B CN 201380072477 A CN201380072477 A CN 201380072477A CN 105142669 B CN105142669 B CN 105142669B
Authority
CN
China
Prior art keywords
sequence
rna
endonuclease
domain
albumen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380072477.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105142669A (zh
Inventor
F.陈
G.D.戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Original Assignee
Sigma Aldrich Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50883989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105142669(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Aldrich Co LLC filed Critical Sigma Aldrich Co LLC
Priority to CN201810574719.4A priority Critical patent/CN108913676B/zh
Priority to CN201810540449.5A priority patent/CN108715602A/zh
Publication of CN105142669A publication Critical patent/CN105142669A/zh
Application granted granted Critical
Publication of CN105142669B publication Critical patent/CN105142669B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380072477.4A 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控 Active CN105142669B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201810574719.4A CN108913676B (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控
CN201810540449.5A CN108715602A (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261734256P 2012-12-06 2012-12-06
US61/734256 2012-12-06
US201361758624P 2013-01-30 2013-01-30
US61/758624 2013-01-30
US201361761046P 2013-02-05 2013-02-05
US61/761046 2013-02-05
US201361794422P 2013-03-15 2013-03-15
US61/794422 2013-03-15
PCT/US2013/073307 WO2014089290A1 (fr) 2012-12-06 2013-12-05 Modification et régulation du génome basées sur crispr

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201810540449.5A Division CN108715602A (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控
CN201810574719.4A Division CN108913676B (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控

Publications (2)

Publication Number Publication Date
CN105142669A CN105142669A (zh) 2015-12-09
CN105142669B true CN105142669B (zh) 2018-07-03

Family

ID=50883989

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810574719.4A Active CN108913676B (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控
CN201810540449.5A Pending CN108715602A (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控
CN201380072477.4A Active CN105142669B (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201810574719.4A Active CN108913676B (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控
CN201810540449.5A Pending CN108715602A (zh) 2012-12-06 2013-12-05 基于crispr的基因组修饰和调控

Country Status (17)

Country Link
US (15) US20160017366A1 (fr)
EP (11) EP3138911B1 (fr)
JP (6) JP6620018B2 (fr)
KR (6) KR102145760B1 (fr)
CN (3) CN108913676B (fr)
AU (9) AU2013355214B2 (fr)
BR (1) BR112015012375A2 (fr)
CA (3) CA2891347C (fr)
DK (6) DK2928496T3 (fr)
ES (6) ES2757325T3 (fr)
HK (1) HK1218389A1 (fr)
IL (5) IL300199A (fr)
LT (4) LT3138911T (fr)
PL (6) PL3138910T3 (fr)
PT (6) PT2928496T (fr)
SG (4) SG10201800585VA (fr)
WO (1) WO2014089290A1 (fr)

Families Citing this family (365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027558A2 (fr) 2006-08-31 2008-03-06 Codon Devices, Inc. Assemblage itératif d'acides nucléiques utilisant l'activation de caractères codés par vecteurs
US10457935B2 (en) 2010-11-12 2019-10-29 Gen9, Inc. Protein arrays and methods of using and making the same
CN103502448B (zh) 2010-11-12 2017-03-29 Gen9股份有限公司 核酸合成的方法和设备
EP3613852A3 (fr) 2011-07-22 2020-04-22 President and Fellows of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
LT2944693T (lt) 2011-08-26 2019-08-26 Gen9, Inc. Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai
US11021737B2 (en) 2011-12-22 2021-06-01 President And Fellows Of Harvard College Compositions and methods for analyte detection
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
AU2013251701A1 (en) 2012-04-24 2014-10-30 Gen9, Inc. Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
CN109536526B (zh) 2012-04-25 2020-06-09 瑞泽恩制药公司 核酸酶介导的使用大靶向载体的靶向
EP3597741A1 (fr) 2012-04-27 2020-01-22 Duke University Correction génétique de gènes ayant subi une mutation
UA118014C2 (uk) 2012-05-25 2018-11-12 Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія Спосіб модифікації днк-мішені
EP2861737B1 (fr) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Ciblage de gène dans des plantes à l'aide de virus à adn
US20150191719A1 (en) 2012-06-25 2015-07-09 Gen9, Inc. Methods for Nucleic Acid Assembly and High Throughput Sequencing
CN105188767A (zh) * 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
CN110669746B (zh) * 2012-10-23 2024-04-16 基因工具股份有限公司 用于切割靶dna的组合物及其用途
CA2891510C (fr) 2012-11-16 2022-10-18 Transposagen Biopharmaceuticals, Inc. Enzymes specifiques de site et procedes d'utilisation associes
IL300199A (en) 2012-12-06 2023-03-01 Sigma Aldrich Co Llc CRISPR-based genome modification and regulation
EP3434776A1 (fr) 2012-12-12 2019-01-30 The Broad Institute, Inc. Procédés, modèles, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
RU2721275C2 (ru) * 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
CA2894668A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Systemes de composants de crispr-cas, procedes et compositions pour la manipulation de sequences
WO2014093694A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Systèmes, procédés et compositions de crispr-nickase cas pour la manipulation de séquences dans les eucaryotes
PL2921557T3 (pl) * 2012-12-12 2017-03-31 Broad Inst Inc Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją
DK2921557T3 (en) 2012-12-12 2016-11-07 Broad Inst Inc Design of systems, methods and optimized sequence manipulation guide compositions
SG10201912327SA (en) 2012-12-12 2020-02-27 Broad Inst Inc Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
ES2741951T3 (es) * 2012-12-17 2020-02-12 Harvard College Modificación por ingeniería genética del genoma humano guiada por ARN
JP2016507244A (ja) * 2013-02-27 2016-03-10 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集
EP2971184B1 (fr) 2013-03-12 2019-04-17 President and Fellows of Harvard College Procédé de génération d'une matrice tridimensionnelle contenant des acides nucléiques
AU2014235794A1 (en) 2013-03-14 2015-10-22 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CA3161835A1 (fr) * 2013-03-15 2014-09-25 The General Hospital Corporation Direction, par guidage arn, de proteines regulatrices genetiques et epigenomiques vers des loci genomiques specifiques
EP2970997A1 (fr) * 2013-03-15 2016-01-20 Regents of the University of Minnesota Ingénierie de génomes de plantes à l'aide de systèmes crispr/cas
US20140273230A1 (en) * 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
WO2014172470A2 (fr) * 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Procedes de mutation, de modification ou de modulation d'acide nucleique dans une cellule ou chez un mammifere non-humain
ES2699578T3 (es) 2013-04-16 2019-02-11 Regeneron Pharma Modificación direccionada del genoma de rata
US9873894B2 (en) 2013-05-15 2018-01-23 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US20160122774A1 (en) * 2013-05-29 2016-05-05 Cellectis A method for producing precise dna cleavage using cas9 nickase activity
BR112015030491A8 (pt) * 2013-06-04 2022-07-26 Harvard College método de modular a expressão de um ácido nucleico alvo em uma célula, bem como método de alterar um ácido nucleico de dna alvo em uma célula
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
KR20230136697A (ko) * 2013-06-05 2023-09-26 듀크 유니버시티 Rna-가이드 유전자 편집 및 유전자 조절
EP3008186B1 (fr) 2013-06-14 2018-11-28 Cellectis Procédés d'édition de génome non transgénique dans des plantes
JP6625971B2 (ja) * 2013-06-17 2019-12-25 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化
AU2014281027A1 (en) * 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
CN113425857A (zh) 2013-06-17 2021-09-24 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
EP3011033B1 (fr) 2013-06-17 2020-02-19 The Broad Institute, Inc. Génomique fonctionnelle utilisant des systèmes crispr-cas, procédés de composition, cribles et applications de ces derniers
AU2014281030B2 (en) * 2013-06-17 2020-07-09 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
WO2014204729A1 (fr) 2013-06-17 2014-12-24 The Broad Institute Inc. Administration, utilisation et applications thérapeutiques de systèmes crispr-cas et compositions pour cibler les troubles et maladies en utilisant des éléments viraux
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US11306328B2 (en) * 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015026886A1 (fr) 2013-08-22 2015-02-26 E. I. Du Pont De Nemours And Company Procédés visant à produire des modifications génétiques dans un génome de végétal sans introduire de marqueur de transgène sélectionnable, et compositions correspondantes
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150079680A1 (en) * 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
WO2015065964A1 (fr) 2013-10-28 2015-05-07 The Broad Institute Inc. Génomique fonctionnelle utilisant des systèmes crispr-cas, compositions, procédés, cribles et applications de ces systèmes
WO2015066119A1 (fr) 2013-10-30 2015-05-07 North Carolina State University Compositions et méthodes liées à un système crispr-cas de type ii chez lactobacillus buchneri
CN111218447A (zh) 2013-11-07 2020-06-02 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
PT3080279T (pt) 2013-12-11 2018-12-17 Regeneron Pharma Métodos e composições para a modificação direcionada de um genoma
WO2015089364A1 (fr) 2013-12-12 2015-06-18 The Broad Institute Inc. Structure cristalline d'un système crispr-cas, et ses utilisations
SG10201804976YA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
CA2932436A1 (fr) 2013-12-12 2015-06-18 The Broad Institute, Inc. Compositions et procedes d'utilisation de systemes crispr-cas dans les maladies dues a une repetition de nucleotides
KR20160097327A (ko) 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
US20150166985A1 (en) * 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
US10787654B2 (en) * 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
CA2938456C (fr) 2014-02-11 2022-06-21 The Regents Of The University Of Colorado, A Body Corporate Ingenierie genomique multiplexe validee ayant recours au systeme crispr
CN106232823A (zh) 2014-02-18 2016-12-14 杜克大学 灭活病毒复制的组合物及其制备和使用方法
EP3114227B1 (fr) 2014-03-05 2021-07-21 Editas Medicine, Inc. Méthodes et compositions liées à crispr/cas et destinées à traiter le syndrome de usher et la rétinite pigmentaire
EP3116997B1 (fr) 2014-03-10 2019-05-15 Editas Medicine, Inc. Méthodes et compositions associées aux crispr/cas, utilisées dans le traitement de l'amaurose congénitale de leber 10 (lca10)
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015148670A1 (fr) * 2014-03-25 2015-10-01 Editas Medicine Inc. Procédés et compositions liés à crispr/cas pour traiter une infection par le vih et le sida
EP3981876A1 (fr) 2014-03-26 2022-04-13 Editas Medicine, Inc. Méthodes liées à crispr/cas et compositions pour le traitement de la drépanocytose
US11439712B2 (en) 2014-04-08 2022-09-13 North Carolina State University Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
EP3152319A4 (fr) * 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Méthodes et compositions pour conception de nucléases
LT3152312T (lt) 2014-06-06 2020-04-27 Regeneron Pharmaceuticals, Inc. Tikslinio lokuso modifikavimo būdai ir kompozicijos
CA2952697A1 (fr) * 2014-06-16 2015-12-23 The Johns Hopkins University Compositions et procedes pour l'expression d'arn guide de crispr a l'aide du promoteur h1
EP3157328B1 (fr) * 2014-06-17 2021-08-04 Poseida Therapeutics, Inc. Procédé pour diriger des protéines vers des loci spécifiques dans le génome et leurs utilisations
JP6336140B2 (ja) 2014-06-23 2018-06-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヌクレアーゼ媒介ｄｎａアセンブリ
PL3161128T3 (pl) 2014-06-26 2019-02-28 Regeneron Pharmaceuticals, Inc. Sposoby i kompozycje do celowanych modyfikacji genetycznych i sposoby zastosowania
US20170198268A1 (en) * 2014-07-09 2017-07-13 Gen9, Inc. Compositions and Methods for Site-Directed DNA Nicking and Cleaving
US11254933B2 (en) * 2014-07-14 2022-02-22 The Regents Of The University Of California CRISPR/Cas transcriptional modulation
CA2956224A1 (fr) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Proteines cas9 comprenant des inteines dependant de ligands
KR20180015731A (ko) * 2014-08-06 2018-02-13 주식회사 툴젠 캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
WO2016033298A1 (fr) 2014-08-28 2016-03-03 North Carolina State University Nouvelles protéines cas9 et éléments de guidage pour le ciblage de l'adn et l'édition du génome
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
US11560568B2 (en) 2014-09-12 2023-01-24 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
WO2016057850A1 (fr) 2014-10-09 2016-04-14 Seattle Children' S Hospital (Dba Seattle Children' S Research Institute) Longs plasmides poly (a) et méthodes d'introduction de longues séquences poly(a) dans le plasmide
EP3998344A1 (fr) * 2014-10-09 2022-05-18 Life Technologies Corporation Oligonucléotides crispr et édition de gènes
AU2015332451A1 (en) 2014-10-15 2017-04-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
WO2016065364A1 (fr) * 2014-10-24 2016-04-28 Life Technologies Corporation Compositions et méthodes pour améliorer la recombinaison homologue
US20190100769A1 (en) * 2014-10-31 2019-04-04 Massachusetts Institute Of Technology Massively parallel combinatorial genetics for crispr
DK3597740T3 (da) * 2014-11-06 2022-06-20 Dupont Us Holding Llc Peptidmedieret indføring af rna-styret endonuklease i celler
CA2963820A1 (fr) 2014-11-07 2016-05-12 Editas Medicine, Inc. Procedes pour ameliorer l'edition genomique mediee par crispr/cas
WO2016077273A1 (fr) * 2014-11-11 2016-05-19 Q Therapeutics, Inc. Manipulation de cellules souches mésenchymateuses par recombinaison homologue
EP3222728B1 (fr) 2014-11-19 2021-07-14 Institute for Basic Science Procédé de régulation de l'expression génique à l'aide de la protéine cas9 exprimée par deux vecteurs
US10457960B2 (en) 2014-11-21 2019-10-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide RNAs
GB201421096D0 (en) 2014-11-27 2015-01-14 Imp Innovations Ltd Genome editing methods
CA2969619A1 (fr) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Arn guide comportant des modifications chimiques
JP6830437B2 (ja) 2014-12-10 2021-02-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 疾患を処置するための遺伝子改変された細胞、組織および臓器
WO2016094867A1 (fr) 2014-12-12 2016-06-16 The Broad Institute Inc. Arn guides protégés (pgrnas)
MX2017008190A (es) 2014-12-19 2018-03-23 Regeneron Pharma Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
EP3234111A1 (fr) 2014-12-19 2017-10-25 Regeneron Pharmaceuticals, Inc. Cellules souches comme modèle du diabète de type 2
BR112017016045A2 (pt) 2015-01-29 2018-04-03 Meiogenix método para induzir recombinações meióticas endereçadas em uma célula eucariótica, proteína de fusão, ácido nucleico, cassete de expressão ou um vetor, célula hospedeira, método para gerar variantes de um organismo eucariótico, método para identificar ou localizar as informações genéticas, kit, e, uso de um kit
AU2016246450B2 (en) 2015-04-06 2022-03-17 Agilent Technologies, Inc. Chemically modified guide RNAs for CRISPR/Cas-mediated gene regulation
KR102535217B1 (ko) 2015-04-24 2023-05-19 에디타스 메디신, 인코포레이티드 Ｃａｓ9 분자/가이드 ｒｎａ 분자 복합체의 평가
US20180156807A1 (en) 2015-04-29 2018-06-07 New York University Method for treating high-grade gliomas
CN108026566A (zh) 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 用于使dna片段化的方法和试剂盒
JP7030522B2 (ja) 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
AU2016270649B2 (en) 2015-05-29 2022-04-21 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
CN108368502B (zh) 2015-06-03 2022-03-18 内布拉斯加大学董事委员会 使用单链dna的dna编辑
CA2986262A1 (fr) 2015-06-09 2016-12-15 Editas Medicine, Inc. Procedes lies a crispr/cas et compositions d'amelioration de la transplantation
DK3307872T3 (da) 2015-06-15 2023-10-23 Univ North Carolina State Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober
ES2886599T3 (es) * 2015-06-17 2021-12-20 Poseida Therapeutics Inc Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
RU2021120582A (ru) 2015-06-18 2021-09-02 Те Брод Инститьют, Инк. Мутации фермента crispr, уменьшающие нецелевые эффекты
WO2016205759A1 (fr) 2015-06-18 2016-12-22 The Broad Institute Inc. Modification et optimisation de systèmes, de méthodes, d'enzymes et d'échafaudages guides d'orthologues de cas9 et variant pour la manipulation de séquences
WO2016210271A1 (fr) * 2015-06-24 2016-12-29 Sigma-Aldrich Co. Llc Modification et régulation génomique dépendantes du cycle cellulaire
GB2595063B (en) 2015-07-31 2022-03-09 Univ Minnesota Modified cells and methods of therapy
EP3334746B1 (fr) 2015-08-14 2021-11-24 The University Of Sydney Inhibition de la connexine 45 pour la thérapie
ES2929110T3 (es) 2015-08-25 2022-11-24 Univ Duke Composiciones y métodos para mejorar la especificidad en ingeniería genética usando endonucleasas guiadas por ARN
CN114875012A (zh) 2015-08-28 2022-08-09 通用医疗公司 工程化的CRISPR-Cas9核酸酶
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CA2999500A1 (fr) 2015-09-24 2017-03-30 Editas Medicine, Inc. Utilisation d'exonucleases pour ameliorer l'edition de genome a mediation par crispr/cas
KR101745863B1 (ko) 2015-09-25 2017-06-12 전남대학교산학협력단 Crispr/cas9 시스템을 이용한 프로히비틴2 유전자 제거용 시발체
KR101795999B1 (ko) 2015-09-25 2017-11-09 전남대학교산학협력단 Crispr/cas9 시스템을 이용한 베타2-마이크로글로불린 유전자 제거용 시발체
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
FI3846375T3 (fi) 2015-10-22 2023-01-13 Menetelmät ja laitteet liittyen radiosignaalien selektiiviseen parantamiseen
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
WO2017079406A1 (fr) 2015-11-03 2017-05-11 President And Fellows Of Harvard College Procédé et appareil pour imagerie volumétrique d'une matrice tridimensionnelle contenant des acides nucléiques
US11905521B2 (en) 2015-11-17 2024-02-20 The Chinese University Of Hong Kong Methods and systems for targeted gene manipulation
US10240145B2 (en) * 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
EA201891619A1 (ru) 2016-01-11 2019-02-28 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Химерные белки и способы регулирования экспрессии генов
WO2017123556A1 (fr) 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Protéines chimériques et procédés d'immunothérapie
EP3219799A1 (fr) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Expression sgrna crispr conditionnelle
EP3433364A1 (fr) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systèmes et procédés pour traiter une déficience en alpha 1-antitrypsine (a1at)
WO2017165826A1 (fr) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systèmes d'édition de génome comprenant des molécules d'enzyme modulant la réparation et leurs procédés d'utilisation
EP3443086B1 (fr) 2016-04-13 2021-11-24 Editas Medicine, Inc. Systèmes d'édition de gènes de molécules de fusion cas9 et leurs procédés d'utilisation
JP7197363B2 (ja) * 2016-04-14 2022-12-27 ボコ シリコン バレー， インコーポレイテッド ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集
CA3022290A1 (fr) 2016-04-25 2017-11-02 President And Fellows Of Harvard College Procedes de reaction en chaine d'hybridation pour la detection moleculaire in situ
EP3448995A1 (fr) * 2016-04-25 2019-03-06 Universität Basel Édition d'allèles et ses applications
EP3457840B1 (fr) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Procédés pour briser la tolérance immunologique à l'aide de multiples arn de guidage
GB2552861B (en) * 2016-06-02 2019-05-15 Sigma Aldrich Co Llc Using programmable DNA binding proteins to enhance targeted genome modification
SG11201810772XA (en) * 2016-06-03 2018-12-28 Inst Nat Sante Rech Med Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof
AU2017277810A1 (en) * 2016-06-03 2018-12-06 Temple University - Of The Commonwealth System Of Higher Education Negative feedback regulation of HIV-1 by gene editing strategy
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
LT3474669T (lt) 2016-06-24 2022-06-10 The Regents Of The University Of Colorado, A Body Corporate Barkodu pažymėtų kombinatorinių bibliotekų generavimo būdai
US11603533B2 (en) 2016-07-12 2023-03-14 Washington University Incorporation of internal polya-encoded poly-lysine sequence tags and their variations for the tunable control of protein synthesis in bacterial and eukaryotic cells
US10266582B2 (en) 2016-07-28 2019-04-23 Regeneron Pharmaceuticals, Inc. GPR156 variants and uses thereof
JP2019523009A (ja) 2016-07-29 2019-08-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃ末端切断型フィブリリン−１の発現をもたらす変異を有するマウス
CA3032822A1 (fr) 2016-08-02 2018-02-08 Editas Medicine, Inc. Compositions et procedes de traitement d'une maladie associee a cep290
WO2018027078A1 (fr) 2016-08-03 2018-02-08 President And Fellows Of Harard College Éditeurs de nucléobases d'adénosine et utilisations associées
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US20190185850A1 (en) * 2016-08-20 2019-06-20 Avellino Lab Usa, Inc. Single guide rna/crispr/cas9 systems, and methods of use thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
WO2018048827A1 (fr) * 2016-09-07 2018-03-15 Massachusetts Institute Of Technology Assemblage d'adn à base d'endonucléases guidées par arn
CN106636197B (zh) * 2016-09-22 2019-09-03 南京市妇幼保健院 一种定向敲降斑马鱼基因组中多拷贝基因的方法
US20190225974A1 (en) 2016-09-23 2019-07-25 BASF Agricultural Solutions Seed US LLC Targeted genome optimization in plants
KR20230170126A (ko) 2016-09-30 2023-12-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
EP3525831A4 (fr) * 2016-10-11 2020-06-03 Stemgenics, Inc. Nanoparticules fonctionnalisées avec des outils d'édition de gène et procédés associés
US20200172899A1 (en) 2016-10-14 2020-06-04 The General Hospital Corporation Epigenetically Regulated Site-Specific Nucleases
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
GB201617559D0 (en) 2016-10-17 2016-11-30 University Court Of The University Of Edinburgh The Swine comprising modified cd163 and associated methods
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
CA3041582A1 (fr) * 2016-11-02 2018-05-11 Universitat Basel Variants de surface cellulaire discernables sur le plan immunologique destines a etre utilises en therapie cellulaire
WO2018117746A1 (fr) * 2016-12-23 2018-06-28 기초과학연구원 Composition pour l'édition de bases pour un embryon animal et procédé d'édition de bases
WO2018119359A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
US11859219B1 (en) 2016-12-30 2024-01-02 Flagship Pioneering Innovations V, Inc. Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
BR112019014841A2 (pt) 2017-01-23 2020-04-28 Regeneron Pharma rna guia, uso do rna guia, rna antissentido, sirna ou shrna, uso do rna antissentido, do sirna ou do shrna, ácido nucleico isolado, vetor, composição, célula, e, métodos para modificar um gene hsd17b13 em uma célula, para diminuir a expressão de um gene hsd17b13 em uma célula, para modificar uma célula e para tratar um indivíduo que não é portador da variante de hsd17b13
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
CN106978438B (zh) * 2017-02-27 2020-08-28 北京大北农生物技术有限公司 提高同源重组效率的方法
EP3592853A1 (fr) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression de la douleur par édition de gène
WO2018165629A1 (fr) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Éditeur de base cytosine à guanine
EP3596217A1 (fr) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systèmes et méthodes pour le traitement d'hémoglobinopathies
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
US11834670B2 (en) 2017-04-19 2023-12-05 Global Life Sciences Solutions Usa Llc Site-specific DNA modification using a donor DNA repair template having tandem repeat sequences
US11591589B2 (en) 2017-04-21 2023-02-28 The General Hospital Corporation Variants of Cpf1 (Cas12a) with altered PAM specificity
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
EP3622070A2 (fr) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/arn-guidé systèmes et procédés nucléases transgéniques
WO2018209320A1 (fr) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
EP3630849A4 (fr) 2017-05-25 2021-01-13 The General Hospital Corporation Architectures d'éditeur de base bipartite (bbe) et édition de doigt de zinc de type ii-c-cas9
EP3635102A1 (fr) 2017-06-05 2020-04-15 Regeneron Pharmaceuticals, Inc. Variants deb4galt1
JP2020524497A (ja) 2017-06-09 2020-08-20 エディタス・メディシン，インコーポレイテッド 操作されたｃａｓ９ヌクレアーゼ
US20200362355A1 (en) 2017-06-15 2020-11-19 The Regents Of The University Of California Targeted non-viral dna insertions
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
JP7278978B2 (ja) 2017-06-27 2023-05-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ａｓｇｒ１座位を含む非ヒト動物
EP3645021A4 (fr) 2017-06-30 2021-04-21 Intima Bioscience, Inc. Vecteurs viraux adéno-associés destinés à la thérapie génique
JP2020530979A (ja) 2017-06-30 2020-11-05 インスクリプタ， インコーポレイテッド 自動細胞処理方法、モジュール、機器及びシステム
WO2019014564A1 (fr) 2017-07-14 2019-01-17 Editas Medicine, Inc. Systèmes et procédés d'intégration ciblée et d'édition du génome et détection de celle-ci à l'aide de sites d'amorçage intégrés
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
SG11201912024RA (en) * 2017-07-31 2020-02-27 Sigma Aldrich Co Llc Synthetic guide rna for crispr/cas activator systems
BR112020001364A2 (pt) 2017-07-31 2020-08-11 Regeneron Pharmaceuticals, Inc. métodos para testar e modificar a capacidade de uma crispr/cas nuclease.
RU2019143568A (ru) 2017-07-31 2021-09-02 Регенерон Фармасьютикалс, Инк. Способы и композиции для оценки crispr/cas-индуцированной рекомбинации с экзогенной донорной нуклеиновой кислотой in vivo
US11021719B2 (en) 2017-07-31 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
ES2960390T3 (es) * 2017-08-09 2024-03-04 Ricetec Inc Composiciones y métodos para modificar genomas
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019050948A1 (fr) * 2017-09-05 2019-03-14 Regeneron Pharmaceuticals, Inc. Administration d'un système d'édition génique comportant une seule particule rétrovirale et méthodes de génération et d'utilisation
JP7237064B2 (ja) 2017-09-06 2023-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 単一免疫グロブリンインターロイキン－１受容体関連（ｓｉｇｉｒｒ）変異型及びその使用
CN111278851A (zh) 2017-09-07 2020-06-12 雷杰纳荣制药公司 溶质运载体家族14成员1(slc14a1)变体及其用途
US20190098879A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
WO2019068022A1 (fr) 2017-09-30 2019-04-04 Inscripta, Inc. Instrumentation d'électroporation à flux continu
MX2020003565A (es) 2017-10-16 2020-10-08 Regeneron Pharma Variantes de cornulina (crnn) y sus usos.
WO2019079195A1 (fr) * 2017-10-16 2019-04-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cellules souches mésenchymateuses génétiquement modifiées destinées à être utilisées dans des prothèses cardiovasculaires
EP3697906A1 (fr) 2017-10-16 2020-08-26 The Broad Institute, Inc. Utilisations d'éditeurs de bases adénosine
CA3080415A1 (fr) 2017-10-27 2019-05-02 The Regents Of The University Of California Remplacement cible de recepteurs de cellules t endogenes
WO2019089808A1 (fr) 2017-11-01 2019-05-09 The Regents Of The University Of California Compositions de crispr/cas de classe 2 et leurs procédés d'utilisation
AU2018366290B2 (en) 2017-11-10 2022-01-27 Regeneron Pharmaceuticals, Inc. Non-human animals comprising Slc30a8 mutation and methods of use
EP3710583A1 (fr) * 2017-11-16 2020-09-23 Astrazeneca AB Compositions et méthodes pour améliorer l'efficacité de stratégies knock-in basées sur cas9
CA3076377A1 (fr) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus trkb humanise
WO2019126578A1 (fr) * 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions et procédés permettant de diriger des protéines vers des loci spécifiques dans le génome
CA3085914A1 (fr) * 2017-12-22 2019-06-27 G+Flas Life Sciences Molecules d'ingenierie genomique chimere et procedes
US20200362366A1 (en) 2018-01-12 2020-11-19 Basf Se Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
US20210047632A1 (en) * 2018-01-26 2021-02-18 The Children's Medical Center Corporation Targeting bcl11a distal regulatory elements with a cas9-cas9 fusion for fetal hemoglobin reinduction
BR112020010479A2 (pt) 2018-02-15 2020-11-24 Sigma-Aldrich Co. Llc sistemas cas9 geneticamente modificados para modificação de genoma eucariótico
JP7334178B2 (ja) 2018-03-19 2023-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ＣＲＩＳＰＲ／Ｃａｓ系を使用した動物での転写モジュレーション
EP3775159A4 (fr) 2018-03-29 2022-01-19 Inscripta, Inc. Régulation automatisée des taux de croissance cellulaire pour l'induction et la transformation
US10376889B1 (en) 2018-04-13 2019-08-13 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
EP3781705A4 (fr) 2018-04-19 2022-01-26 The Regents of the University of California Compositions et méthodes pour l'édition génique
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
WO2019209926A1 (fr) 2018-04-24 2019-10-31 Inscripta, Inc. Instrumentation automatisée pour la production de bibliothèques de peptides
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
WO2019209912A2 (fr) * 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Édition thérapeutique du génome dans le syndrome hyper-igm lié au sexe
WO2019213910A1 (fr) * 2018-05-10 2019-11-14 Syngenta Participations Ag Procédés et compositions pour l'édition ciblée de polynucléotides
CN112513271A (zh) 2018-05-10 2021-03-16 奥克索利提克有限公司 使用营养缺陷型可调控细胞进行基因治疗的方法和组合物
JP2021523745A (ja) 2018-05-16 2021-09-09 シンテゴ コーポレイション ガイドｒｎａ設計および使用のための方法およびシステム
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
EP3575402A1 (fr) * 2018-06-01 2019-12-04 Algentech SAS Ciblage de gènes
WO2019234754A1 (fr) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Constructions d'acide nucléique et procédés d'utilisation de celles-ci
CA3102975A1 (fr) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Procedes de regeneration et de transformation de cannabis
CN112469834A (zh) * 2018-06-25 2021-03-09 生物纳米基因公司 Dna的标记
AU2019316094A1 (en) * 2018-08-03 2021-02-25 Beam Therapeutics Inc. Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
GB201813011D0 (en) 2018-08-10 2018-09-26 Vib Vzw Means and methods for drought tolerance in crops
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10533152B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
KR102103103B1 (ko) 2018-08-16 2020-04-21 (주)라트바이오 인위적 뉴클레아제를 생산하는 형질전환 동물 및 형질전환 배아
SG11202101382VA (en) * 2018-08-21 2021-03-30 Sigma Aldrich Co Llc Down-regulation of the cytosolic dna sensor pathway
WO2020081149A2 (fr) 2018-08-30 2020-04-23 Inscripta, Inc. Détection améliorée de séquences à édition par nucléase dans des modules automatisés et des instruments
CN109055379B (zh) * 2018-09-10 2022-04-15 石铭 一种转基因鸡输卵管生物反应器的制备方法
KR102121817B1 (ko) * 2018-09-12 2020-06-26 한국화학연구원 Crispr 편집 기술을 이용한 재조합 항원을 발현시키는 벡터 및 이를 동시에 다중 삽입시키는 방법
CA3112612C (fr) 2018-09-13 2024-02-27 Regeneron Pharmaceuticals, Inc. Rat a invalidation genique de facteur h de complement en tant que modele de glomerulopathie c3
WO2020072248A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant
GB2593353B (en) 2018-10-16 2023-03-01 Blueallele Corp Methods for targeted insertion of DNA in genes
EP3870697A4 (fr) 2018-10-22 2022-11-09 Inscripta, Inc. Enzymes modifiées
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
WO2020086908A1 (fr) * 2018-10-24 2020-04-30 The Broad Institute, Inc. Constructions pour édition génomique dépendante de la hdr améliorée
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
US10934536B2 (en) 2018-12-14 2021-03-02 Pioneer Hi-Bred International, Inc. CRISPR-CAS systems for genome editing
WO2020128478A1 (fr) 2018-12-19 2020-06-25 King's College London Procédés et compositions immunothérapeutiques
JP7449291B2 (ja) 2018-12-20 2024-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヌクレアーゼ媒介リピート伸長
JP2022516919A (ja) * 2019-01-04 2022-03-03 ザ・ユニバーシティ・オブ・シカゴ Ｒｎａをモジュレートするためのシステムおよび方法
WO2020146899A1 (fr) * 2019-01-11 2020-07-16 Chan Zuckerberg Biohub, Inc. Modification ciblée du génome in vivo
WO2020163396A1 (fr) 2019-02-04 2020-08-13 The General Hospital Corporation Variants d'éditeur de base d'adn adénine avec édition d'arn hors cible réduite
EP3924477A4 (fr) * 2019-02-14 2023-03-29 Metagenomi, Inc. Enzymes ayant des domaines ruvc
EP3924475A1 (fr) * 2019-02-15 2021-12-22 Sigma-Aldrich Co. LLC Protéines et systèmes de fusion crispr/cas
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
EP4219700A1 (fr) 2019-03-07 2023-08-02 The Regents of the University of California Polypeptides effecteurs crispr-cas et leurs procédés d'utilisation
US11781131B2 (en) 2019-03-18 2023-10-10 Regeneron Pharmaceuticals, Inc. CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
JP7461368B2 (ja) 2019-03-18 2024-04-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タウの播種または凝集の遺伝的修飾因子を同定するためのｃｒｉｓｐｒ／ｃａｓスクリーニングプラットフォーム
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020198174A1 (fr) 2019-03-25 2020-10-01 Inscripta, Inc. Édition simultanée de génome multiplex dans une levure
JP2022527809A (ja) 2019-04-03 2022-06-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体コード配列をセーフハーバー遺伝子座に挿入するための方法および組成物
US11737435B2 (en) 2019-04-04 2023-08-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
AU2020253531C1 (en) 2019-04-04 2022-06-16 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
GB201905360D0 (en) 2019-04-16 2019-05-29 Univ Nottingham Fungal strains, production and uses thereof
CN113825838A (zh) 2019-05-10 2021-12-21 巴斯夫欧洲公司 增强植物中基因表达的调节性核酸分子
JP2022534867A (ja) 2019-06-04 2022-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
CN113939593A (zh) 2019-06-06 2022-01-14 因思科瑞普特公司 用于递归的核酸指导的细胞编辑的处治
AU2020289581A1 (en) 2019-06-07 2021-11-18 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
AU2020290509A1 (en) 2019-06-14 2021-11-11 Regeneron Pharmaceuticals, Inc. Models of tauopathy
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
WO2020257395A1 (fr) 2019-06-21 2020-12-24 Inscripta, Inc. Mutations de conception rationnelle à l'échelle du génome conduisant à une production améliorée de lysine dans e. coli
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
WO2021050398A1 (fr) * 2019-09-10 2021-03-18 The Regents Of The University Of California Plate-forme de criblage de létalité synthétique pour cellules subissant un alt
BR112022004545A2 (pt) 2019-09-12 2022-05-31 Basf Se Métodos para aumentar a expressão derivada de um promotor vegetal e produzir uma planta, construção de expressão recombinante, vetor de expressão, célula ou planta transgênica, cultura de células transgênicas e usos
CN114616002A (zh) 2019-09-13 2022-06-10 瑞泽恩制药公司 使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控
WO2021069387A1 (fr) 2019-10-07 2021-04-15 Basf Se Molécules d'acide nucléique régulatrices pour améliorer l'expression génique dans des plantes
CN110628825A (zh) * 2019-10-14 2019-12-31 上海捷易生物科技有限公司 一种依赖nhej的报告基因敲入组合物及其使用方法
MX2022005572A (es) 2019-11-08 2022-06-09 Regeneron Pharma Estrategias crispr y aav para la terapia de retinosquisis juvenil ligada al cromosoma x.
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021108363A1 (fr) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Régulation à la hausse médiée par crispr/cas d'un allèle ttr humanisé
CN114787365A (zh) 2019-12-03 2022-07-22 巴斯夫欧洲公司 用于在植物中增强基因表达的调节性核酸分子
KR20220110778A (ko) 2019-12-10 2022-08-09 인스크립타 인코포레이티드 신규 mad 뉴클레아제
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
WO2021122080A1 (fr) 2019-12-16 2021-06-24 BASF Agricultural Solutions Seed US LLC Édition génomique améliorée à l'aide de nickases appariées
US11008557B1 (en) 2019-12-18 2021-05-18 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
EP4087600A4 (fr) * 2020-01-09 2024-01-24 Pioneer Hi-Bred International, Inc. Échange de gène en deux étapes
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
CA3157061A1 (fr) 2020-01-27 2021-08-05 Christian SILTANEN Modules d'electroporation et instrumentation
WO2021154791A1 (fr) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus pnpla3 humanisé et procédés d'utilisation
US20230081547A1 (en) 2020-02-07 2023-03-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
AU2021232598A1 (en) 2020-03-04 2022-09-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for sensitization of tumor cells to immune therapy
EP4125348A1 (fr) 2020-03-23 2023-02-08 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus ttr humanisé affichant une mutation v30m et méthodes d'utilisation
WO2021202568A1 (fr) 2020-03-31 2021-10-07 Metagenomi Ip Technologies, Llc Systèmes crispr de classe ii, type ii
US20210319851A1 (en) 2020-04-03 2021-10-14 Creyon Bio, Inc. Oligonucleotide-based machine learning
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
EP4171215A2 (fr) 2020-06-26 2023-05-03 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus d'ace2 humanisé
CN111849986A (zh) * 2020-07-24 2020-10-30 江苏集萃药康生物科技有限公司 一种减少CRISPR-Cas9基因编辑中双链DNA片段串联的方法及其应用
WO2022060749A1 (fr) 2020-09-15 2022-03-24 Inscripta, Inc. Édition par crispr pour incorporer des plaques d'amarrage d'acide nucléique dans des génomes de cellules vivantes
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
US20240002839A1 (en) 2020-12-02 2024-01-04 Decibel Therapeutics, Inc. Crispr sam biosensor cell lines and methods of use thereof
WO2022133139A2 (fr) * 2020-12-16 2022-06-23 Administrators Of The Tulane Educational Fund Adipocytes wnt+, exosomes d'adipocyte wnt+, et leurs procédés de fabrication et d'utilisation
AU2021415461A1 (en) 2021-01-04 2023-08-17 Inscripta, Inc. Mad nucleases
EP4274890A1 (fr) 2021-01-07 2023-11-15 Inscripta, Inc. Nucléases mad
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
GB202103131D0 (en) 2021-03-05 2021-04-21 Biosystems Tech Limited Method for preparation of research organisms
WO2022240846A1 (fr) 2021-05-10 2022-11-17 Sqz Biotechnologies Company Méthodes pour administrer des molécules d'édition génomique au noyau ou au cytosol d'une cellule et leurs utilisations
WO2022251644A1 (fr) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Cellules immunitaires déficientes en nr4a3 et leurs utilisations
WO2022256437A1 (fr) 2021-06-02 2022-12-08 Lyell Immunopharma, Inc. Cellules immunitaires déficientes en nr4a3 et leurs utilisations
AU2022343300A1 (en) 2021-09-10 2024-04-18 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
WO2023064924A1 (fr) 2021-10-14 2023-04-20 Codiak Biosciences, Inc. Cellules productrices modifiées pour la production de vésicules extracellulaires
WO2023077053A2 (fr) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions associés à crispr/cas pour la désactivation de c5
IL312452A (en) 2021-11-01 2024-06-01 Tome Biosciences Inc A transformant has a single structure for the simultaneous transfer of a gene editing mechanism and a nucleic acid cargo
CA3231899A1 (fr) 2021-11-04 2023-05-11 Trevor Stitt Animaux non humains comprenant un locus cacng1 modifie
AU2022408167A1 (en) 2021-12-08 2024-06-06 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
GB202118058D0 (en) 2021-12-14 2022-01-26 Univ Warwick Methods to increase yields in crops
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023122506A1 (fr) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant des loci ace2 et tmprss humanisés
WO2023122764A1 (fr) 2021-12-22 2023-06-29 Tome Biosciences, Inc. Co-administration d'une construction d'éditeur génique et d'un patron donneur
AU2022424002A1 (en) 2021-12-29 2024-06-13 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023150181A1 (fr) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Méthodes et compositions pour le traitement du cancer
WO2023150620A1 (fr) 2022-02-02 2023-08-10 Regeneron Pharmaceuticals, Inc. Insertion de transgène médiée par crispr dans des cellules néonatales
WO2023150798A1 (fr) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions et procédés permettant de définir des délais de traitement optimaux dans le cadre d'une maladie lysosomale
WO2023205744A1 (fr) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Compositions d'insertion de gènes programmable
WO2023212677A2 (fr) 2022-04-29 2023-11-02 Regeneron Pharmaceuticals, Inc. Identification de zones de sécurité extragéniques spécifiques de tissu pour des approches de thérapie génique
WO2023215831A1 (fr) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Compositions d'arn guide pour insertion de gène programmable
WO2023220603A1 (fr) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vecteurs et procédés de production d'anticorps in vivo
WO2023225665A1 (fr) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucléotides ciblant nr4a3 et leurs utilisations
WO2023225670A2 (fr) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Insertion de gène programmable ex vivo
WO2023235725A2 (fr) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Agents thérapeutiques à base de crispr pour une maladie d'expansion de répétition c9orf72
WO2023235726A2 (fr) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Agents thérapeutiques d'interférence crispr pour une maladie d'expansion de répétition c9orf72
WO2023250384A2 (fr) * 2022-06-22 2023-12-28 The Regents Of The University Of California Polypeptides effecteurs crispr-cas et leurs procédés d'utilisation
GB2621813A (en) 2022-06-30 2024-02-28 Univ Newcastle Preventing disease recurrence in Mitochondrial replacement therapy
WO2024020587A2 (fr) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Insertion de gènes programmable par des cellules souches pléiopluripotentes
WO2024026488A2 (fr) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus de récepteur de transférrine modifié
WO2024026474A1 (fr) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions et méthodes d'administration médiée par le récepteur de la transferrine (tfr) au cerveau et au muscle
WO2024031053A1 (fr) 2022-08-05 2024-02-08 Regeneron Pharmaceuticals, Inc. Variants de tdp-43 résistants à l'agrégation
WO2024064952A1 (fr) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a surexprimant c-jun
WO2024064958A1 (fr) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2024073606A1 (fr) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Récepteurs modifiés résistants aux anticorps pour améliorer des thérapies à base de cellules
WO2024077174A1 (fr) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2024083579A1 (fr) 2022-10-20 2024-04-25 Basf Se Molécules d'acide nucléique régulatrices pour améliorer l'expression génique dans des plantes
US20240182561A1 (en) 2022-11-04 2024-06-06 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107765A2 (fr) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions et procédés d'administration médiée par le récepteur 3 du facteur de croissance des fibroblastes à des astrocytes
WO2024107670A1 (fr) 2022-11-16 2024-05-23 Regeneron Pharmaceuticals, Inc. Protéines chimériques comprenant une il-12 liée à une membrane avec des lieurs clivables par protéase

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
WO1988008450A1 (fr) 1987-05-01 1988-11-03 Birdwell Finlayson Therapie genetique pour troubles du metabolisme
US5350689A (en) 1987-05-20 1994-09-27 Ciba-Geigy Corporation Zea mays plants and transgenic Zea mays plants regenerated from protoplasts or protoplast-derived cells
US5767367A (en) 1990-06-23 1998-06-16 Hoechst Aktiengesellschaft Zea mays (L.) with capability of long term, highly efficient plant regeneration including fertile transgenic maize plants having a heterologous gene, and their preparation
US7150982B2 (en) 1991-09-09 2006-12-19 Third Wave Technologies, Inc. RNA detection assays
FR2763797B1 (fr) * 1997-05-30 1999-07-16 Tabacs & Allumettes Ind Cigarette a tres faible taux de goudron presentant un gout de tabac comparable a celui d'une cigarette classique a plus fort taux de goudron
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20020182673A1 (en) 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
AU2982900A (en) 1999-02-03 2000-08-25 Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US8183339B1 (en) * 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20020119570A1 (en) 2000-09-25 2002-08-29 Kyonggeun Yoon Targeted gene correction by single-stranded oligodeoxynucleotides
EP2277894A1 (fr) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
WO2002074968A1 (fr) * 2001-03-16 2002-09-26 Naoya Kobayashi Procede de proliferation d'une cellule hepatique, cellule hepatique obtenue a l'aide de ce procede et utilisation de cette cellule hepatique
KR101021695B1 (ko) 2001-07-12 2011-03-15 유니버시티 오브 매사추세츠 유전자 불활성화를 매개하는 소형 간섭 ｒｎａ의 생체내 제조
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
WO2003080809A2 (fr) 2002-03-21 2003-10-02 Sangamo Biosciences, Inc. Procedes et compositions permettant d'utiliser des endonucleases a doigts de zinc pour ameliorer la recombinaison homologue
WO2003087993A2 (fr) 2002-04-09 2003-10-23 Beattie Kenneth L Sondes oligonucleotidiques pour puces de genocapteur
WO2003104451A2 (fr) * 2002-06-06 2003-12-18 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Modification de recombinaison et de reparation d'adn
EP1581610A4 (fr) 2002-09-05 2009-05-27 California Inst Of Techn Utilisation de nucleases chimeres pour stimuler le ciblage de genes
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
AU2004263865B2 (en) 2003-08-08 2007-05-17 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
WO2005070948A1 (fr) 2004-01-23 2005-08-04 Intronn, Inc. Correction de defauts genetiques lies a l'alpha-1-antitrypsine par transepissage d'arn a mediation par spliceosome
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050220796A1 (en) 2004-03-31 2005-10-06 Dynan William S Compositions and methods for modulating DNA repair
US7919277B2 (en) 2004-04-28 2011-04-05 Danisco A/S Detection and typing of bacterial strains
JP2008525029A (ja) * 2004-12-22 2008-07-17 ニュークレオニクス・インコーポレイテッド 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
US7892224B2 (en) 2005-06-01 2011-02-22 Brainlab Ag Inverse catheter planning
US7534819B2 (en) 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
US20060282289A1 (en) 2005-06-14 2006-12-14 Healthmatch Solutions, Llc System and method for health care financing
US20100055793A1 (en) * 2005-07-25 2010-03-04 Johns Hopkins University Site-specific modification of the human genome using custom-designed zinc finger nucleases
CN101273141B (zh) * 2005-07-26 2013-03-27 桑格摩生物科学股份有限公司 外源核酸序列的靶向整合和表达
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
EP3284833B1 (fr) 2005-08-26 2021-12-01 DuPont Nutrition Biosciences ApS Utilisation de genes associes à crispr (cas)
KR100877824B1 (ko) * 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
EP1991706B1 (fr) * 2006-03-02 2014-01-15 The Ohio State University Research Foundation Profil d'expression de micro-arn associé au cancer du pancréas
US9677123B2 (en) 2006-03-15 2017-06-13 Siemens Healthcare Diagnostics Inc. Degenerate nucleobase analogs
US20110257377A1 (en) * 2006-03-28 2011-10-20 Barnett Susan W Covalently linked complexes of HIV TAT and ENV PROTEINS
ES2367661T3 (es) 2006-05-10 2011-11-07 Deinove Proceso de ingeniería cromosómica mediante el uso de un nuevo sistema de reparación del adn.
ES2373586T3 (es) 2006-05-19 2012-02-06 Danisco A/S Microorganismos marcados y métodos para marcar.
JP5551432B2 (ja) 2006-05-25 2014-07-16 サンガモ バイオサイエンシーズ， インコーポレイテッド 遺伝子不活性化のための方法と組成物
EP2034848B1 (fr) 2006-06-16 2016-10-19 DuPont Nutrition Biosciences ApS Bactérie streptococcus thermophilus
EP2054514A4 (fr) * 2006-08-04 2009-11-04 Univ Georgia State Res Found Capteurs d'enzyme, procédés de préparation et utilisation de tels capteurs, et procédés de détection de l'activité protéase
NZ592231A (en) 2007-03-02 2012-07-27 Danisco Methods to generate bacteriophage resistant bacterial strains and produce bacteriophage CRISPR loci phage mutants
GB0806086D0 (en) 2008-04-04 2008-05-14 Ulive Entpr Ltd Dendrimer polymer hybrids
US8546553B2 (en) 2008-07-25 2013-10-01 University Of Georgia Research Foundation, Inc. Prokaryotic RNAi-like system and methods of use
CA2734235C (fr) 2008-08-22 2019-03-26 Sangamo Biosciences, Inc. Procedes et compositions pour un clivage simple brin cible et une integration ciblee
ES2615829T3 (es) 2008-09-15 2017-06-08 The Children's Medical Center Corporation Modulación de BCL11A para el tratamiento de hemoglobinopatías
US20100076057A1 (en) * 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
US10662227B2 (en) 2008-11-07 2020-05-26 Dupont Nutrition Biosciences Aps Bifidobacteria CRISPR sequences
EP2789687A1 (fr) 2008-12-12 2014-10-15 DuPont Nutrition Biosciences ApS Groupe génétique de souches de Streptococcus thermophilus dotés de propriétés rhéologiques uniques pour la fermentation lactique
WO2010075424A2 (fr) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions et procédés de réduction de gènes procaryotes
GB0823658D0 (en) 2008-12-30 2009-02-04 Angiomed Ag Stent delivery device
US8392349B2 (en) 2009-02-23 2013-03-05 Shalini Vajjhala Global adaptation atlas and method of creating same
US9834787B2 (en) 2009-04-09 2017-12-05 Sangamo Therapeutics, Inc. Targeted integration into stem cells
SG175839A1 (en) 2009-04-30 2011-12-29 San Raffaele Centro Fond Gene vector
JP2013500018A (ja) 2009-07-24 2013-01-07 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー ゲノム編集のための方法
US20120192298A1 (en) * 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
EP2727600B1 (fr) 2009-07-28 2019-03-27 Sangamo Therapeutics, Inc. Protéines fusionées à doigts de zinc pour supprimer un gène de huntington
US8586526B2 (en) * 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
KR101418355B1 (ko) 2009-10-23 2014-07-11 (주)바이오니아 고밀도 유전자 합성기
DE102009052674B4 (de) 2009-11-12 2012-10-18 Karl Weinhold Verfahren und Vorrichtung zum Verbinden von Doppelmantelrohren
US20110294114A1 (en) 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
CN106834320B (zh) 2009-12-10 2021-05-25 明尼苏达大学董事会 Tal效应子介导的dna修饰
EP2660318A1 (fr) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Modification génomique ciblée de molécules partiellement donneuses à simple brin
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
BR112012028805A2 (pt) 2010-05-10 2019-09-24 The Regents Of The Univ Of California E Nereus Pharmaceuticals Inc composições de endorribonuclease e métodos de uso das mesmas.
WO2011156430A2 (fr) 2010-06-07 2011-12-15 Fred Hutchinson Cancer Research Center Génération et expression d'endonucléase i-onul génétiquement modifiée et ses homologues et utilisations
EP2392208B1 (fr) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Protéines de fusion comportant un domaine de liaison ADN d'une protéine TAL effectrice et domaine de clivage non spécifique d'une nucléase de restriction et leur utilisation
CA2802360A1 (fr) 2010-06-14 2011-12-22 Iowa State University Research Foundation, Inc. Activite nuclease d'un effecteur tal et d'une proteine de fusion foki
BR112013001685B1 (pt) * 2010-07-23 2021-10-13 Sigma-Aldrich Co. Llc Método para editar pelo menos uma sequência cromossômica endógena em uma célula pela inserção de uma sequência na sequência cromossômica
WO2012018697A1 (fr) 2010-08-02 2012-02-09 Integrated Dna Technologies, Inc. Procédés pour prédire les températures de stabilité et de fusion de doubles hélices d'acide nucléique
WO2012054726A1 (fr) 2010-10-20 2012-04-26 Danisco A/S Séquences de gènes associés à lactococcus crispr-cas
US9403880B2 (en) * 2010-11-26 2016-08-02 Institut Pasteur Identification of a human gyrovirus and applications
US20120214241A1 (en) 2010-12-22 2012-08-23 Josee Laganiere Zinc finger nuclease modification of leucine rich repeat kinase 2 (lrrk2) mutant fibroblasts and ipscs
KR20120096395A (ko) 2011-02-22 2012-08-30 주식회사 툴젠 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법
WO2012164565A1 (fr) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions et procédés pour la régulation à la baisse de gènes procaryotes
KR102209330B1 (ko) 2011-09-21 2021-01-29 상가모 테라퓨틱스, 인코포레이티드 이식 유전자 발현의 조절을 위한 방법 및 조성물
WO2013074999A1 (fr) * 2011-11-16 2013-05-23 Sangamo Biosciences, Inc. Protéines de liaison d'adn modifiées et utilisations de celles-ci
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
RU2650811C2 (ru) 2012-02-24 2018-04-17 Фред Хатчинсон Кэнсер Рисерч Сентер Композиции и способы лечения гемоглобинопатии
CA2865011C (fr) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Procedes et compositions permettant de traiter la maladie de huntington
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (fr) 2012-03-20 2013-09-26 Vilnius University Clivage d'adn dirigé par arn par le complexe cas9-arncr
AU2013204327B2 (en) 2012-04-20 2016-09-01 Aviagen Cell transfection method
US11518997B2 (en) 2012-04-23 2022-12-06 BASF Agricultural Solutions Seed US LLC Targeted genome engineering in plants
CN109536526B (zh) 2012-04-25 2020-06-09 瑞泽恩制药公司 核酸酶介导的使用大靶向载体的靶向
CN104428414B (zh) 2012-05-02 2022-01-21 陶氏益农公司 苹果酸脱氢酶的靶向修饰
KR102116153B1 (ko) 2012-05-07 2020-05-27 상가모 테라퓨틱스, 인코포레이티드 도입유전자의 뉴클레아제-매개 표적화된 통합을 위한 방법 및 조성물
WO2013169398A2 (fr) 2012-05-09 2013-11-14 Georgia Tech Research Corporation Systèmes et procédés pour améliorer la spécificité et l'activité de nucléases
UA118014C2 (uk) * 2012-05-25 2018-11-12 Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія Спосіб модифікації днк-мішені
US20140056868A1 (en) 2012-05-30 2014-02-27 University of Washington Center for Commercialization Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement
US9102936B2 (en) 2012-06-11 2015-08-11 Agilent Technologies, Inc. Method of adaptor-dimer subtraction using a CRISPR CAS6 protein
WO2013188522A2 (fr) 2012-06-12 2013-12-19 Genentech, Inc. Procédés et compositions pour la génération d'allèles à inactivation conditionnelle
EP2674501A1 (fr) 2012-06-14 2013-12-18 Agence nationale de sécurité sanitaire de l'alimentation,de l'environnement et du travail Composition de catalyseur pour la polymérisation des oléfines
US9688971B2 (en) 2012-06-15 2017-06-27 The Regents Of The University Of California Endoribonuclease and methods of use thereof
EP2861737B1 (fr) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Ciblage de gène dans des plantes à l'aide de virus à adn
EP2872154B1 (fr) 2012-07-11 2017-05-31 Sangamo BioSciences, Inc. Procédés et compositions pour la délivrance d'agents biologiques
EP2872625B1 (fr) 2012-07-11 2016-11-16 Sangamo BioSciences, Inc. Compositions et méthodes pour le traitement des maladies lysosomales
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
EP2880171B1 (fr) 2012-08-03 2018-10-03 The Regents of The University of California Procédés et compositions permettant de réguler l'expression génique par maturation de l'arn
EP2890780B8 (fr) 2012-08-29 2020-08-19 Sangamo Therapeutics, Inc. Procédés et compositions de traitement d'un état génétique
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
CA2884162C (fr) 2012-09-07 2020-12-29 Dow Agrosciences Llc Loci de performance fad3 et proteines se liant a un site specifique cible correspondantes pouvant induire des cassures ciblees
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
US20150267176A1 (en) 2012-10-12 2015-09-24 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
CN110669746B (zh) * 2012-10-23 2024-04-16 基因工具股份有限公司 用于切割靶dna的组合物及其用途
KR20150100651A (ko) 2012-10-30 2015-09-02 리컴비네틱스 인코포레이티드 동물의 성적 성숙 조절
CA2890160A1 (fr) 2012-10-31 2014-05-08 Cellectis Couplage de la resistance aux herbicides a l'insertion ciblee de transgenes chez la plante
US20140127752A1 (en) 2012-11-07 2014-05-08 Zhaohui Zhou Method, composition, and reagent kit for targeted genomic enrichment
IL300199A (en) 2012-12-06 2023-03-01 Sigma Aldrich Co Llc CRISPR-based genome modification and regulation
WO2014093479A1 (fr) 2012-12-11 2014-06-19 Montana State University Contrôle de la régulation génétique guidé par arn crispr (répétitions palindromiques groupées, courtes régulièrement espacées )
DK2921557T3 (en) 2012-12-12 2016-11-07 Broad Inst Inc Design of systems, methods and optimized sequence manipulation guide compositions
EP3434776A1 (fr) 2012-12-12 2019-01-30 The Broad Institute, Inc. Procédés, modèles, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés
EP2931899A1 (fr) 2012-12-12 2015-10-21 The Broad Institute, Inc. Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications
RU2721275C2 (ru) 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
CA2894668A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Systemes de composants de crispr-cas, procedes et compositions pour la manipulation de sequences
PL2921557T3 (pl) 2012-12-12 2017-03-31 Broad Inst Inc Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
SG10201912327SA (en) 2012-12-12 2020-02-27 Broad Inst Inc Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
WO2014093694A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Systèmes, procédés et compositions de crispr-nickase cas pour la manipulation de séquences dans les eucaryotes
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
WO2014093736A1 (fr) 2012-12-13 2014-06-19 Dow Agrosciences Llc Procédés de détection d'adn pour activité de nucléase spécifique à un site
ES2741951T3 (es) 2012-12-17 2020-02-12 Harvard College Modificación por ingeniería genética del genoma humano guiada por ARN
EP3491915B1 (fr) 2012-12-27 2023-05-31 Keygene N.V. Procédé d'induction d'une translocation ciblee dans une plante
AU2014207618A1 (en) 2013-01-16 2015-08-06 Emory University Cas9-nucleic acid complexes and uses related thereto
CN103233028B (zh) 2013-01-25 2015-05-13 南京徇齐生物技术有限公司 一种无物种限制无生物安全性问题的真核生物基因打靶方法及螺旋结构dna序列
WO2014127287A1 (fr) 2013-02-14 2014-08-21 Massachusetts Institute Of Technology Procédé pour la mutagenèse ciblée in vivo
ES2904803T3 (es) 2013-02-20 2022-04-06 Regeneron Pharma Modificación genética de ratas
WO2014130955A1 (fr) 2013-02-25 2014-08-28 Sangamo Biosciences, Inc. Méthodes et compositions pour améliorer une disruption génique à médiation nucléase
AU2014235794A1 (en) 2013-03-14 2015-10-22 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
EP2970997A1 (fr) 2013-03-15 2016-01-20 Regents of the University of Minnesota Ingénierie de génomes de plantes à l'aide de systèmes crispr/cas
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CA3161835A1 (fr) 2013-03-15 2014-09-25 The General Hospital Corporation Direction, par guidage arn, de proteines regulatrices genetiques et epigenomiques vers des loci genomiques specifiques
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US20140364333A1 (en) 2013-03-15 2014-12-11 President And Fellows Of Harvard College Methods for Live Imaging of Cells
CN105518146B (zh) 2013-04-04 2022-07-15 哈佛学院校长同事会 利用CRISPR/Cas系统的基因组编辑的治疗性用途
RU2723130C2 (ru) 2013-04-05 2020-06-08 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы и композиции для встраивания экзогенной последовательности в геном растений
ES2699578T3 (es) 2013-04-16 2019-02-11 Regeneron Pharma Modificación direccionada del genoma de rata
CN103224947B (zh) 2013-04-28 2015-06-10 陕西师范大学 一种基因打靶系统
JP2016518142A (ja) 2013-05-10 2016-06-23 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
US20140349405A1 (en) 2013-05-22 2014-11-27 Wisconsin Alumni Research Foundation Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
EP3011033B1 (fr) 2013-06-17 2020-02-19 The Broad Institute, Inc. Génomique fonctionnelle utilisant des systèmes crispr-cas, procédés de composition, cribles et applications de ces derniers
WO2014204729A1 (fr) 2013-06-17 2014-12-24 The Broad Institute Inc. Administration, utilisation et applications thérapeutiques de systèmes crispr-cas et compositions pour cibler les troubles et maladies en utilisant des éléments viraux
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
AU2014281030B2 (en) 2013-06-17 2020-07-09 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
CN113425857A (zh) 2013-06-17 2021-09-24 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
CN103382468B (zh) * 2013-07-04 2015-04-29 中国科学院遗传与发育生物学研究所 一种水稻基因组定点改造方法
CN103343120B (zh) 2013-07-04 2015-03-04 中国科学院遗传与发育生物学研究所 一种小麦基因组定点改造方法
AU2014287397B2 (en) 2013-07-10 2019-10-10 President And Fellows Of Harvard College Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
CN103388006B (zh) 2013-07-26 2015-10-28 华东师范大学 一种基因定点突变的构建方法
US10421957B2 (en) 2013-07-29 2019-09-24 Agilent Technologies, Inc. DNA assembly using an RNA-programmable nickase
UA121459C2 (uk) 2013-11-04 2020-06-10 Дау Агросаєнсиз Елелсі Рекомбінантна молекула нуклеїнової кислоти для трансформації рослини сої
BR102014027436B1 (pt) 2013-11-04 2022-06-28 Dow Agrosciences Llc Molécula de ácido nucleico recombinante, e método para a produção de uma célula vegetal transgênica
JP6633532B2 (ja) 2013-11-04 2020-01-22 ダウ アグロサイエンシィズ エルエルシー 最適なトウモロコシ遺伝子座
CN111218447A (zh) 2013-11-07 2020-06-02 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
US9850525B2 (en) 2014-01-29 2017-12-26 Agilent Technologies, Inc. CAS9-based isothermal method of detection of specific DNA sequence
WO2015117041A1 (fr) 2014-01-30 2015-08-06 Nair Ramesh B Procédés et compositions à médiation par la modification de gènes pour produire des traits dominants dans les systèmes eucaryotes
US20150225801A1 (en) 2014-02-11 2015-08-13 California Institute Of Technology Recording and mapping lineage information and molecular events in individual cells
WO2015127439A1 (fr) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Méthodes et compositions pour l'intégration ciblée médiée par les nucléases
EP3929279A1 (fr) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Procédés et compositions de régulation de l'expression de protéines en doigt de zinc

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A CRISPR approach to gene targeting;DANA CARROLL;《Molecular therapy》;20120901;第20卷(第9期);1658-1660 *
as9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria;Giedrius Gasiunas et al;《 PNAS 》;20120904;E2579–E2586 *
The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli;Rimantas Sapranauskas et al;《Nucleic Acids Research》;20110803;9275–9282 *

Also Published As

Publication number Publication date
IL267598B (en) 2022-05-01
EP3138909A1 (fr) 2017-03-08
KR102006880B1 (ko) 2019-08-02
DK3363902T3 (da) 2020-01-02
IL291129A (en) 2022-05-01
LT3138911T (lt) 2019-02-25
EP2928496A1 (fr) 2015-10-14
EP3138912A1 (fr) 2017-03-08
LT3363902T (lt) 2020-02-10
JP7478772B2 (ja) 2024-05-07
KR102145760B1 (ko) 2020-08-19
DK3138911T3 (en) 2019-01-21
JP2022115994A (ja) 2022-08-09
ES2713243T3 (es) 2019-05-20
US20210388396A1 (en) 2021-12-16
EP3360964B1 (fr) 2019-10-02
US20160298132A1 (en) 2016-10-13
IL291129B1 (en) 2023-03-01
PL3360964T3 (pl) 2020-03-31
JP2016502840A (ja) 2016-02-01
PT2928496T (pt) 2019-11-11
EP3135765A1 (fr) 2017-03-01
IL238856B (en) 2018-03-29
EP3617309A2 (fr) 2020-03-04
US20160298134A1 (en) 2016-10-13
JP2021101706A (ja) 2021-07-15
PL3363902T3 (pl) 2020-05-18
KR102243092B1 (ko) 2021-04-22
IL267598A (en) 2019-08-29
PL3138910T3 (pl) 2018-01-31
EP2928496A4 (fr) 2017-03-01
ES2714154T3 (es) 2019-05-27
AU2022200330B2 (en) 2023-11-09
CA2891347C (fr) 2018-02-27
KR102531576B1 (ko) 2023-05-11
EP3363902A1 (fr) 2018-08-22
US20210207173A1 (en) 2021-07-08
US20160298137A1 (en) 2016-10-13
BR112015012375A2 (pt) 2017-09-26
US20160298125A1 (en) 2016-10-13
CA3034794A1 (fr) 2014-06-12
AU2019201344B2 (en) 2020-09-03
US20160298135A1 (en) 2016-10-13
DK3138912T3 (en) 2019-01-21
US20160298133A1 (en) 2016-10-13
CA2977152A1 (fr) 2014-06-12
CA2977152C (fr) 2019-04-09
SG10201910987SA (en) 2020-01-30
PL3138911T3 (pl) 2019-04-30
PT3360964T (pt) 2019-10-29
PT3138912T (pt) 2018-12-28
ES2757808T3 (es) 2020-04-30
PL2928496T3 (pl) 2020-04-30
EP3138911B1 (fr) 2018-12-05
LT3138910T (lt) 2017-11-10
US10745716B2 (en) 2020-08-18
JP2019037231A (ja) 2019-03-14
PT3138911T (pt) 2018-12-28
PT3363902T (pt) 2019-12-19
KR102479178B1 (ko) 2022-12-19
KR20230003624A (ko) 2023-01-06
ES2653212T3 (es) 2018-02-06
DK3360964T3 (da) 2019-10-28
AU2013355214A1 (en) 2015-06-04
EP3363902B1 (fr) 2019-11-27
SG10201800585VA (en) 2018-02-27
IL291129B2 (en) 2023-07-01
AU2017204031B2 (en) 2018-06-14
EP3141604A1 (fr) 2017-03-15
AU2018229489A1 (en) 2018-10-04
EP3138912B1 (fr) 2018-12-05
ES2769310T3 (es) 2020-06-25
KR20180011351A (ko) 2018-01-31
US20170191082A1 (en) 2017-07-06
IL257178B (en) 2019-07-31
EP2928496B1 (fr) 2019-10-09
ES2757325T3 (es) 2020-04-28
KR20210045515A (ko) 2021-04-26
HK1218389A1 (zh) 2017-02-17
CN108913676A (zh) 2018-11-30
AU2022200330A1 (en) 2022-02-17
IL257178A (en) 2018-03-29
PT3138910T (pt) 2017-10-18
EP3138911A1 (fr) 2017-03-08
AU2020230246A1 (en) 2020-10-01
CA2891347A1 (fr) 2014-06-12
AU2020230243B2 (en) 2021-10-21
US20200140897A1 (en) 2020-05-07
AU2020273316A1 (en) 2020-12-17
EP3360964A1 (fr) 2018-08-15
AU2017204031A1 (en) 2017-07-06
AU2019201344C1 (en) 2020-12-24
JP2017192392A (ja) 2017-10-26
KR20230070065A (ko) 2023-05-19
AU2019201344A1 (en) 2019-03-21
US20170073705A1 (en) 2017-03-16
DK2928496T3 (da) 2019-11-11
LT3138912T (lt) 2019-02-25
KR20200098727A (ko) 2020-08-20
EP3617309A3 (fr) 2020-05-06
AU2018229489B2 (en) 2018-12-06
US20160298138A1 (en) 2016-10-13
CN108715602A (zh) 2018-10-30
EP3611263A1 (fr) 2020-02-19
CN105142669A (zh) 2015-12-09
WO2014089290A1 (fr) 2014-06-12
EP3138910B1 (fr) 2017-09-20
EP3138910A1 (fr) 2017-03-08
KR20150091052A (ko) 2015-08-07
KR20190093680A (ko) 2019-08-09
US20160298136A1 (en) 2016-10-13
DK3138910T3 (en) 2017-10-16
AU2023216829A1 (en) 2023-09-14
AU2020230243A1 (en) 2020-10-01
US20160017366A1 (en) 2016-01-21
SG10202107423UA (en) 2021-08-30
SG11201503824SA (en) 2015-06-29
CN108913676B (zh) 2023-11-03
KR101844123B1 (ko) 2018-04-02
IL238856A0 (en) 2015-06-30
IL300199A (en) 2023-03-01
AU2013355214B2 (en) 2017-06-15
US10731181B2 (en) 2020-08-04
AU2020273316B2 (en) 2023-05-18
AU2020230246B2 (en) 2020-11-05
JP2020120674A (ja) 2020-08-13
JP6620018B2 (ja) 2019-12-11
PL3138912T3 (pl) 2019-04-30
US20210079427A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
CN105142669B (zh) 基于crispr的基因组修饰和调控
US20210207165A1 (en) Crispr-based genome modification and regulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1218389

Country of ref document: HK

CB03 Change of inventor or designer information

Inventor after: F .chen

Inventor after: G.D. Davies

Inventor before: F.Chen

Inventor before: G. D. Davies

Inventor before: Q. Kang

Inventor before: S. W. Nate

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant